Back to Ovarian Cancer

NCT02873962

NCT02873962
Active, Not Recruiting Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with ovarian cancer, fallopian tube cancer, or peritoneal cancer, confirmed by a tissue or cell sample — any cancer type or grade is accepted
  • You have already received a first round of platinum-based chemotherapy (a common type of cancer treatment)
  • Your cancer has come back after standard treatment
  • Your cancer came back between 2 months and 12 months after your last platinum-based chemotherapy (the exact time window may depend on which group within the trial you are being considered for — confirm with trial site)
  • You have received no more than 3 chemotherapy treatments in total (there is no limit on prior hormone therapies)
  • Your cancer can be measured on scans using standard measurement guidelines
  • You have previously received the drug bevacizumab, as long as you did not have serious harmful reactions to it
  • You have NOT previously received certain immunotherapy drugs that target the immune system's "checkpoint" pathways (such as anti-PD-1, anti-PD-L1, anti-CTLA-4 treatments)
  • Any hormone therapy you were taking has been stopped at least 1 week before starting this trial (hormone replacement therapy for menopause symptoms may be continued)
  • You are 18 years old or older
  • Your doctor estimates you have a life expectancy of more than 6 months
  • You are generally well enough to care for yourself and carry out light activity (confirm with trial site what this means for you)
  • Your recent blood test results meet certain minimum levels for blood cells, kidney function, liver function, and blood clotting — taken within 14 days before joining (confirm specific values with trial site)
  • You have had a previous skin cancer (certain types), early-stage breast or cervical abnormality, or certain early-stage cancers that were fully treated, with no signs of return for at least 3 years
  • You have a tumor that can be biopsied and are willing to have a biopsy before treatment, or you have a stored tumor sample taken within the last 20 months
  • If you are a woman who could become pregnant, you must agree to use effective contraception for 6 months after the last dose of treatment
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 24 hours before starting treatment
  • You are not currently breastfeeding
  • You are able to understand and sign a consent form agreeing to take part
  • For certain groups (Cohorts 2 and 3): You have been tested for a gene change called BRCA and do not carry a harmful BRCA mutation (confirm with trial site)

Who may not be able to join:

  • Your cancer came back less than 2 months after your last platinum-based chemotherapy (called "platinum-refractory" disease)
  • Your cancer came back more than 12 months after your last platinum-based chemotherapy
  • You have had chemotherapy or radiotherapy within the last 3 weeks, or you are still experiencing side effects from a recent treatment
  • You are currently taking part in another clinical trial or have done so within the past 4 weeks
  • You are using natural herbal products or folk remedies, or are unwilling to stop using them during the trial
  • You have had a serious allergic reaction to bevacizumab or to drugs similar to nivolumab or bevacizumab
  • You currently have active cancer that has spread to the brain or the lining around the brain, unless it was treated at least 6 months ago with no signs of return
  • You have certain heart conditions, including a heart attack in the last 6 months, unstable chest pain, severe heart failure, significant heart valve problems, or abnormal heart rhythms requiring a pacemaker (confirm full list with trial site)
  • You have had a hypertensive crisis (a sudden dangerous rise in blood pressure) at any time
  • Your blood pressure is not well controlled (above 140/90 mmHg)
  • You have significant blood vessel disease, including a history of stroke, mini-stroke, or brain bleed
  • Your heart's electrical activity shows certain abnormalities on a heart tracing (ECG) test
  • You have significant protein or blood in your urine
  • You have had a bowel blockage, a hole in your bowel, or an abscess in your abdomen within the last 6 months, or currently have any signs of bowel problems
  • You

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Active, Not Recruiting
Phase
Phase 2
Sponsor
Dana-Farber Cancer Institute
Registry
clinicaltrials_gov
Start date
10 November 2016
Est. completion
1 February 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cohort 1: Objective Response Rate; Cohort 2: Objective Response Rate; Cohort 3: Tolerability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov